HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.

Abstract
Targeting the ubiquitin+proteasome protein degradation pathway with the therapeutic agent bortezomib has significantly improved the survival of cancer patients but drug resistance inevitably develops. Aggresomes and the autophagy pathway serve as compensatory protein-clearance mechanisms that eradicate potentially toxic proteins to promote resistance to proteasome inhibitors and, hence, tumor survival. Pre-clinical evidence has emerged to demonstrate active crosstalk between these protein degradation pathways and has revealed novel therapeutic targets and strategies. Translational research and clinical trials are now focused on these pathways to prevent the emergence of drug resistance, enhance apoptosis and further improve the survival of cancer patients.
AuthorsJames J Driscoll, Roopa De Chowdhury
JournalCancer letters (Cancer Lett) Vol. 325 Issue 2 Pg. 147-54 (Dec 28 2012) ISSN: 1872-7980 [Electronic] Ireland
PMID22781397 (Publication Type: Journal Article, Review)
CopyrightPublished by Elsevier Ireland Ltd.
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Neoplasm Proteins
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Pyrazines
  • Ubiquitin
  • 3-methyladenine
  • Bortezomib
  • Chloroquine
  • Proteasome Endopeptidase Complex
  • Adenine
Topics
  • Adenine (analogs & derivatives, pharmacology)
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Autophagy (drug effects, physiology)
  • Boronic Acids (pharmacology, therapeutic use)
  • Bortezomib
  • Chloroquine (pharmacology)
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Forecasting
  • Humans
  • Inclusion Bodies (metabolism)
  • Medical Oncology
  • Molecular Targeted Therapy
  • Neoplasm Proteins (metabolism)
  • Neoplasms (drug therapy, metabolism)
  • Protease Inhibitors (pharmacology, therapeutic use)
  • Proteasome Endopeptidase Complex (physiology)
  • Proteasome Inhibitors
  • Proteolysis (drug effects)
  • Pyrazines (pharmacology, therapeutic use)
  • Translational Research, Biomedical
  • Ubiquitin (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: